27692-35-9

Usage

InChI:InChI=1/C8H10ClNO/c9-5-6-11-8-3-1-7(10)2-4-8/h1-4H,5-6,10H2

Upstream product

• 36616-28-1 2-(4-acetamidophenoxy)ethyl chloride 
• 103-90-2 4-acetaminophenol 
• 3383-72-0 1-(2-chloroethoxy)-4-nitrobenzene 
• 100-02-7 4-nitro-phenol 
• 50375-15-0 2-[4-(acetylamino)phenoxy]ethanol 

Downstream Products

• 38519-24-3 [4-(2-chloro-ethoxy)-phenyl]-(6-methoxy-benzothiazol-2-yl)-amine 
• 38519-25-4 [4-(2-chloro-ethoxy)-phenyl]-(6-chloro-5-methoxy-benzothiazol-2-yl)-amine 
• 23831-73-4 3-[4-(2-Chloro-ethoxy)-phenyl]-1,1-dimethyl-urea 
• 23831-76-7 1-[4-(2-Chloro-ethoxy)-phenyl]-3-methyl-urea 
• 23831-72-3 C₁₁H₁₅ClN₂O₃ 
• 401514-13-4 4-[2-(3-benzyl-3,8-diaza-bicyclo[3.2.1]oct-8-yl)-ethoxy]-phenylamine 
• 38519-97-0 (6-chloro-5-methoxy-benzothiazol-2-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-amine 
• 62345-76-0 4-<2-(dimethylamino)ethoxy>aniline 
• 242477-99-2 2-amino-N-[4-(2-chloro-ethoxy)-phenyl]-4-methoxy-benzamide 
• 242478-08-6 2-amino-N-[4-(2-chloro-ethoxy)-phenyl]-3-methoxy-benzamide 
• 38519-26-5 [4-(2-chloro-ethoxy)-phenyl]-(5-methoxy-benzothiazol-2-yl)-amine 

Relevant academic research and scientific papers

Dithiocarbamate type compound used as BTK (Bruton Tyrosine Kinase) inhibitor

The invention aims at providing a dithiocarbamate type compound used as a BTK (Bruton Tyrosine Kinase) inhibitor and a pharmaceutical composition thereof, a preparation method and application. The compound provided by the invention has a structure shown as a general formula (I). The formula (I) is shown in the description.

Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors

Bruton's tyrosine kinase (BTK) has emerged as an attractive target related to B-lymphocytes dysfunctions, especially hematologic malignancies and autoimmune diseases. In our study, a series of diphenylaminopyrimidine derivatives bearing dithiocarbamate moieties were designed and synthesized as novel BTK inhibitors for treatment of B-cell lymphoma. Among all these compounds, 30ab (IC50 = 1.15 ± 0.19 nM) displays similar or more potent inhibitory activity against BTK than spebrutinib (IC50 = 2.12 ± 0.32 nM) and FDA approved drug ibrutinib (IC50 = 3.89 ± 0.57 nM), which is attributed to close binding of 30ab with BTK predicted by molecular docking. In particular, 30ab exhibits enhanced anti-proliferative activity against B-lymphoma cell lines at the IC50 concentration of 0.357 ± 0.02 μM (Ramos) and 0.706 ± 0.05 μM (Raji), respectively, almost 10-fold better than ibrutinib and spebrutinib. In addition, 30ab displays stronger selectivity on B-cell lymphoma over other cancer cell lines than spebrutinib. Furthermore, 30ab efficiently blocks BTK downstream pathways and results in apoptosis of cancer cells. In vivo xenograft model evaluation demonstrates the significant efficacy and broad safety margin of 30ab in treatment of B-cell lymphoma. We propose that compound 30ab is a candidate for further study and development based on our current findings.

DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS

Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IGF-IR INHIBITORS

The present invention relates to a compound of formula (I) and derivatives thereof. Furthermore, the invention relates to the use of such compounds as medicaments. In addition, the invention relates to the use of such compounds for manufacturing a medicament useful for treating proliferative diseases.

PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES

The invention relates to phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives - alone or in combination with one or more other pharmaceutically active compounds - for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.

3,8-Diazabicyclo-[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent

Ambasilide, a representative of Class III antiarrhythmics, was reported to prolong the cardiac action potential duration in the dog, with little or no effect on Ca and Na currents. We synthesised a series of ambasilide analogues, having the 3,8-diazabicyclo-[3.2.1]-octane moiety instead of the 3,7-diazabicyclo-[3.3.1]-nonane present in ambasilide. The compounds were tested both in vitro extracellular electrophysiological assays and by the conventional microelectrode technique. Most of them lengthened the effective refractory period (ERP) with no change or slight increase on the impulse conduction time (ICT). Similarly some of the tested compounds lengthened the action potential duration (APD), a typical Class III feature, without exerting any significant effect on the maximal rate of depolarization, therefore apparently lacking Class I antiarrythmic activity.

2- OR 3-(SUBSTITUTEDAMINOALKOXYPHENYL)QUINAZOLIN-4-ONES

This invention relates to 2-or 3-(substituted aminoalkoxyphenyl) quinazolin-4-ones which are partial estrogen agonists and are useful in treating osteoporosis, prostatic hypertrophy, breast cancer and endometrial cancer.

Syntheses of Reactive Fluorescent Stains Derived from 5(2)-Aryl-2(5)-(4-pyridyl)oxazoles and Bifunctionally Reactive Linkers

Several bifunctionally reactive linkers containing halide or sulfonate ester groups were prepared.The linkers were used to quaternize 5-(4-methoxyphenyl)-2-(4-pyridyl)oxazole and 2-(6-chromanyl)-5-(4-pyridyl)oxazole to produce fluorescent stains that contained a reactive group such as an isothiocyanate, an N-hydroxysuccinimidyl ester, a maleimide, or an oxirane.The stains were derivatized with either 1-propyl-amine, 1-propanethiol, or piperidine, as appropriate, to help in characteriazation.The stains may serve as more photostable alternatives to fluoresceins or coumarins.

Anilinobenzothiazoles as antidepressants

New anilinobenzothiazoles are used for treating depression.

Urea derivatives and their use as herbicides

Compounds, useful as herbicides, of the formula SPC1 Wherein R1 is haloalkyl, halocycloalkyl, haloalkenyl, or halocycloalkenyl; n1 is 1 or 2; R4 is halogen, trifluoromethyl, alkyl, or alkoxy; n2 is 0, 1, 2, or 3; R2 is hydrogen or alkyl; and R3 is alkyl or alkoxy. Methods for making these compounds.